Five-year outcomes of the PRESERVE II Zenith iliac branch pivotal clinical study.

OBJECTIVE

PRESERVE II was an Investigational Device Exemption pivotal study performed to evaluate the safety and effectiveness of the Zenith Iliac Branch Graft (ZBIS) with the iCast covered stent system in patients with aortoiliac or iliac aneurysms having a morphology suitable for endovascular repair.

METHODS

PRESERVE II was a prospective, nonrandomized, single-arm, multicenter, clinical study conducted among 18 sites in the United States. Patients were enrolled between 2014 and 2015, with follow-up to 5 years. The primary end point was 6-month freedom from patency-related interventions. Secondary end points were 30-day freedom from morbidity and 6-month branch vessel patency.

RESULTS

Forty patients (95% male; mean age, 67.8 years) were treated; technical success was 100%. Six-month freedom from patency-related intervention was 100% (39/39), 30-day freedom from morbidity was 85% (34/40), and 6-month branch vessel patency was 100% (37/37). Major complications occurred in 10 patients through follow-up. These included a cardiac event requiring intervention (n = 1), ileus (n = 1), leg ischemia (n = 1), stroke (n = 2), buttock claudication ipsilateral to the ZBIS (n = 1), and impotence (n = 5). Five-year follow-up was available in 75% of patients (30/40), with complete imaging in 86.7% of available patients (26/30). Freedom from all-cause mortality at 5 years was 88.9%. There was no aneurysm-related mortality. There were four occlusions related to the ZBIS through follow-up: two in the external iliac artery segment and two in the internal iliac artery segment. In total, four patients required six secondary interventions related to the ZBIS device through 5 years. The treated iliac aneurysm size decreased in 26.9% of patients (7/26) and remained unchanged in 73.1% (19/26) at 5 years. A single case of ipsilateral iliac aneurysm growth was recorded at 4 years post procedure, associated with a type Ic endoleak. There were no ruptures, type III endoleaks, migrations, or device integrity issues.

CONCLUSIONS

The results of the PRESERVE II study met its performance goals for both primary and secondary end points, with higher performance rates than the expected targets. Long-term outcomes support the sustained safety and effectiveness of the ZBIS in combination with the iCast covered stent to preserve hypogastric artery perfusion during endovascular aneurysm repair.